NCT02864407 - Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

3,223

Participants

Timeline

Start Date

December 19, 2016

Primary Completion Date

January 20, 2021

Study Completion Date

January 20, 2021

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)

The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.

Trial Locations (1)

61469

Chonnam National University Hospital, One Or Multiple Sites